Settle down guys - here are the facts !! ........
Prima has done 5 phase I studys on CVac until they found what worked. Then they completed a phase II study and are doing a second phase IIb for a ?Potency Assay? and to comply with US FDA IND. The phase III will provide ?statistical significance for US FDA and EU EMA approval?
On Abagovomab see this news
http://www.medpagetoday.com/MeetingCoverage/ASCO/26956
For Abagovomab mode of delivery(CA-125 monoclonal antibody) mimicked the previously failed phase III study of Oregovomab in 2009
See article on Oregovomab
http://jco.ascopubs.org/content/27/3/418.full
Notice the author is Dr Jonathan Berek on why Oregovomab failed. The expert call from Dr Berek on why CVac is a winner
Listen to this opinion on
http://www.investorcalendar.com/IC/CEPage.asp?ID=163542
- Forums
- ASX - By Stock
- IMM
- abagovomab vs oregovomab - facts ...
abagovomab vs oregovomab - facts ...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $569.8M |
Open | High | Low | Value | Volume |
40.0¢ | 40.0¢ | 39.0¢ | $1.746M | 4.422M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7395 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.5¢ | 94636 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7395 | 0.395 |
11 | 507295 | 0.390 |
12 | 433222 | 0.385 |
21 | 656016 | 0.380 |
5 | 305455 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.405 | 94636 | 3 |
0.410 | 250000 | 2 |
0.415 | 100000 | 1 |
0.420 | 47658 | 4 |
0.425 | 35972 | 2 |
Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online